Current Landscape of Relapsed/ Refractory Multiple Myeloma
Panelists discuss how the current treatment landscape for relapsed/refractory multiple myeloma (R/R MM) includes standard options like such as IMiDs, PIs, and mAbs, while highlighting the emergence of novel therapies such as CAR T- cells and bispecific antibodies, which address unmet needs and offer potential advantages in treatment efficacy and patient outcomes.
Video content above is prompted by the following:
- Provide an overview of the current treatment landscape for R/R MM.
- Briefly discuss standard treatment options (e.g.eg, IMiDs, PIs,, and mAbs).
- Highlight the emergence of novel therapies (eg, CAR T-cells, ADCs antibody-drug conjugates, and bispecifics).
- Discuss the unmet needs in R/R MM treatment.
- Discuss challenges with current therapies (e.g.eg, resistance, and toxicities).
- Discuss patient populations with limited options.
- Introduce bispecific antibodies in the context of R/R MM.
- Discuss their Basic mechanism of action.
- Highlight currently approved bispecifics and those in late-stage development.
- Discuss the potential advantages of bispecific antibodies over other treatment modalities.
- How has the introduction of bispecifics changed your approach to treating R/R MM?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
